WendyStockwHF9BKIeOfnamXNnYUHhvWD+6g==Wendy Stock41.78927490000000-87.601250000000001502Stock, WendyProfessorplugins:TwitterTwitterprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:orcidIdORCID idvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 1001944Authorship 1012347Authorship 1015351Authorship 1001865Authorship 10062612Authorship 101377227634020Leonard JT, Stock WBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationThe Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What? Biol Blood Marrow Transplant. 2016 11; 22(11):1913-1914.Biol Blood Marrow Transplant2016-09-12T00:00:002016The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What?27949624Odenike O, Green M, Larson RA, Rich ES, Ott J, Ratain MJ, Stock WJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms. J Clin Oncol. 2008 May 20; 26(15_suppl):7057.J Clin Oncol2008-05-20T00:00:002008Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms.27949960Stock W, Najib K, Moser BK, Powell BL, Holowka N, Gulati K, Bloomfield CD, Larson RA, Sher DJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710). J Clin Oncol. 2008 May 20; 26(15_suppl):7002.J Clin Oncol2008-05-20T00:00:002008High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710).27949590DeAngelo D, O'Brien SM, Vey N, Seiter K, Stock W, Cahill A, Pigneux A, Claxton D, Stuart R, Giles FJJournal of clinical oncology : official journal of the American Society of Clinical OncologyA double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7051.J Clin Oncol2008-05-20T00:00:002008A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML).28209594Wolfson J, Sun CL, Wyatt L, Stock W, Bhatia SCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyAdolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):312-320.Cancer Epidemiol Biomarkers Prev2017-02-16T00:00:002017Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.28278716Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock WLeukemia & lymphomaEfficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.Leuk Lymphoma2017-02-20T00:00:002017Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.Authorship 101888228299756Brunner AM, Stock WOncology (Williston Park, N.Y.)Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML. Oncology (Williston Park). 2017 Mar 15; 31(3):190, 192.Oncology (Williston Park)2017-03-15T00:00:002017Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.Authorship 102195228355969Christ TN, Stock W, Knoebel RWJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersIncidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018 Jun; 24(4):299-308.J Oncol Pharm Pract2017-03-29T00:00:002017Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.D000970Chemicals & Drugs40723510.435461Antineoplastic AgentsD000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsAuthorship 1100015Authorship 1121847Authorship 11225913Authorship 11286514Authorship 11301319Authorship 1130172Authorship 1130975Authorship 1119487Authorship 11370112Authorship 1114912Authorship 1142359Authorship 1146033Authorship 1145546Authorship 1145842Authorship 1149304Authorship 1152753Authorship 1162889Authorship 1168361Authorship 11629110Authorship 1171668Authorship 1129652Authorship 1183911Authorship 1186572Authorship 1187619Authorship 1143169Authorship 1144084Authorship 1162012Authorship 12037616Authorship 1207553Authorship 1208253Authorship 1210518Authorship 1235136Authorship 1241588Authorship 1227624Authorship 1246808Authorship 1246333Authorship 11814312Authorship 1200412Authorship 1201721Authorship 12053010Authorship 1215905Authorship 12281013Authorship 124464212399973Mata-Greenwood E, Cuendet M, Sher D, Gustin D, Stock W, Pezzuto JMLeukemiaBrusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia. 2002 Nov; 16(11):2275-84.Leukemia2002-11-01T00:00:002002Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc.11726826Bartholomew A, Sher D, Sosler S, Stock W, Lazda V, Koshy M, Devine S, vanBesien KTransplantationStem cell transplantation eliminates alloantibody in a highly sensitized patient. Transplantation. 2001 Nov 27; 72(10):1653-5.Transplantation2001-11-27T00:00:002001Stem cell transplantation eliminates alloantibody in a highly sensitized patient.12356125Verma A, Stock W, Lait M, Ferrer K, Quinn J, Platanias LCSouthern medical journalActinomycosis presenting as an oral ulcer in a neutropenic patient. South Med J. 2002 Sep; 95(9):1105.South Med J2002-09-01T00:00:002002Actinomycosis presenting as an oral ulcer in a neutropenic patient.28889888Chen LW, McShane PJ, Karkowsky W, Gray SE, Adegunsoye A, Stock W, Artz A, White SR, Montner SM, Strek MEChestDe Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest. 2017 09; 152(3):683-685.Chest2017-09-01T00:00:002017De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy.30006258Hantel A, Stock W, Kosuri SClinical lymphoma, myeloma & leukemiaMolecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647.Clin Lymphoma Myeloma Leuk2018-06-27T00:00:002018Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.10776761Stock W, Hoffman RLancet (London, England)White blood cells 1: non-malignant disorders. Lancet. 2000 Apr 15; 355(9212):1351-7.Lancet2000-04-15T00:00:002000White blood cells 1: non-malignant disorders.29381191Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HMCancerEfficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.Cancer2018-01-30T00:00:002018Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.29344432Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock WExperimental hematology & oncologyWT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol. 2018; 7:1.Exp Hematol Oncol2018-01-11T00:00:002018WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.11148680Verma A, Stock WCurrent opinion in oncologyManagement of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol. 2001 Jan; 13(1):14-20.Curr Opin Oncol2001-01-01T00:00:002001Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach.11166464Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman RExperimental hematologyMesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol. 2001 Feb; 29(2):244-55.Exp Hematol2001-02-01T00:00:002001Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.29661880Wassermann T, Reimer EK, McKinnon M, Stock WAntimicrobial agents and chemotherapyRefractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole. Antimicrob Agents Chemother. 2018 07; 62(7).Antimicrob Agents Chemother2018-06-26T00:00:002018Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.29211308Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJCancerDose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334.Cancer2017-12-06T00:00:002017Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.29222234Leonard J, Stock WHematology. American Society of Hematology. Education ProgramProgress in adult ALL: incorporation of new agents to frontline treatment. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):28-36.Hematology Am Soc Hematol Educ Program2017-12-08T00:00:002017Progress in adult ALL: incorporation of new agents to frontline treatment.30423270Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RAJournal of oncology practiceTreatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657.J Oncol Pract2018-11-01T00:00:002018Treatment of Acute Promyelocytic Leukemia in Adults.30466749Rank CU, Stock WBest practice & research. Clinical haematologyShould immunologic strategies be incorporated into frontline ALL therapy? Best Pract Res Clin Haematol. 2018 12; 31(4):367-372.Best Pract Res Clin Haematol2018-09-25T00:00:002018Should immunologic strategies be incorporated into frontline ALL therapy?28844816Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJThe Lancet. OncologyGuadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326.Lancet Oncol2017-08-24T00:00:002017Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.11014896Usha L, Bradlow B, Stock W, Platanias LCActa haematologicaCD5+ immunophenotype in the bone marrow but not in the peripheral blood in a patient with hairy cell leukemia. Acta Haematol. 2000; 103(4):210-3.Acta Haematol2000-01-01T00:00:002000CD5+ immunophenotype in the bone marrow but not in the peripheral blood in a patient with hairy cell leukemia.29450465Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, Reed D, Lewis M, Freyer DR, Shah B, Luger S, Hayes-Lattin B, Jaboin JJ, Coccia PF, DeAngelo DJ, Seibel N, Bleyer AJAMA oncologyPediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2018 05 01; 4(5):725-734.JAMA Oncol2018-05-01T00:00:002018Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.29288821Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz ASBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationReduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.Biol Blood Marrow Transplant2017-12-27T00:00:002017Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.29296715Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YLBlood advancesClonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017 May 09; 1(12):715-727.Blood Adv2017-05-02T00:00:002017Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.29496700Wynne J, Stock WBlood"Dar"-ing to target CD38 in T-ALL. Blood. 2018 03 01; 131(9):948-949.Blood2018-03-01T00:00:002018"Dar"-ing to target CD38 in T-ALL.29463550Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JEClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303.Clin Cancer Res2018-02-20T00:00:002018Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.29296758DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani ASBlood advancesInotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017 Jun 27; 1(15):1167-1180.Blood Adv2017-06-27T00:00:002017Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.29304833Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu HJournal of hematology & oncologyA phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.J Hematol Oncol2018-01-05T00:00:002018A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.29330398Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes MBone marrow transplantationManagement of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.Bone Marrow Transplant2018-01-12T00:00:002018Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.30393935Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JHPediatric blood & cancerOutcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 03; 66(3):e27542.Pediatr Blood Cancer2018-11-04T00:00:002018Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).29034366Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RABlood advancesA phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017 Jan 24; 1(5):331-340.Blood Adv2017-01-24T00:00:002017A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.10733508Stock W, Tsai T, Golden C, Rankin C, Sher D, Slovak ML, Pallavicini MG, Radich JP, Boldt DHBloodCell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood. 2000 Apr 01; 95(7):2364-71.Blood2000-04-01T00:00:002000Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia.29128555Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien KBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationCombined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.Biol Blood Marrow Transplant2017-11-08T00:00:002017Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.30058716Siegel SE, Advani A, Seibel N, Muffly L, Stock W, Luger S, Shah B, DeAngelo DJ, Freyer DR, Douer D, Johnson RH, Hayes-Lattin B, Lewis M, Jaboin JJ, Coccia PF, Bleyer AAmerican journal of hematologyTreatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol. 2018 10; 93(10):1254-1266.Am J Hematol2018-09-03T00:00:002018Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.30070150D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz ASLeukemia & lymphomaCharacterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.Leuk Lymphoma2018-08-02T00:00:002018Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.8996121Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT, Sher DA, Wu D, Le Beau MM, Schiffer CA, Bloomfield CDJournal of clinical oncology : official journal of the American Society of Clinical OncologyValue of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 Jan; 15(1):26-36.J Clin Oncol1997-01-01T00:00:001997Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.29741514Muffly LS, Reizine N, Stock WClinical advances in hematology & oncology : H&OManagement of acute lymphoblastic leukemia in young adults. Clin Adv Hematol Oncol. 2018 Feb; 16(2):138-146.Clin Adv Hematol Oncol2018-02-01T00:00:002018Management of acute lymphoblastic leukemia in young adults.Authorship 1257581030567725Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RABlood advancesRandomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.Blood Adv2018-12-26T00:00:002018Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).Authorship 1264913Authorship 1264924Authorship 126523430622841Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu HExperimental hematology & oncologyOutcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1.Exp Hematol Oncol2019-01-03T00:00:002019Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.30622147Wynne J, Wright D, Stock WBlood advancesInotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 01 08; 3(1):96-104.Blood Adv2019-01-08T00:00:002019Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.30623490Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HMAmerican journal of hematologyPrognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416.Am J Hematol2019-01-17T00:00:002019Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.Authorship 12668145Authorship 126697130643249Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CGNature geneticsPAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.Nat Genet2019-01-14T00:00:002019PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.30658992Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RABloodA pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 04 04; 133(14):1548-1559.Blood2019-01-18T00:00:002019A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.Authorship 100711Authorship 116314Authorship 120282Authorship 128062230796026Curran E, Stock WBloodTaking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL. Blood. 2019 04 18; 133(16):1715-1719.Blood2019-02-22T00:00:002019Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.Authorship 128520430920645Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani ASCancerInotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.Cancer2019-03-28T00:00:002019Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.Authorship 13401Authorship 129308631039409Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2019 09; 25(9):1720-1729.Biol Blood Marrow Transplant2019-04-27T00:00:002019Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.Authorship 1294534Authorship 1294561231060979Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MRThe Lancet. HaematologyGuadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.Lancet Haematol2019-05-03T00:00:002019Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.31056348Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain NClinical lymphoma, myeloma & leukemiaOral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.Clin Lymphoma Myeloma Leuk2019-03-26T00:00:002019Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.Authorship 183781Authorship 224115Authorship 202526Authorship 1301431331217161van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SOBlood advancesHaploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.Blood Adv2019-06-25T00:00:002019Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.Authorship 210102Authorship 248824Authorship 248977Authorship 2907119Authorship 132447931446198DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf DBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123.Biol Blood Marrow Transplant2019-08-22T00:00:002019Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.Authorship 293211Authorship 259333Authorship 281647Authorship 286873Authorship 351611Authorship 260827Authorship 268243Authorship 348641Authorship 383671Authorship 3435417Authorship 3975911Authorship 281191Authorship 289249Authorship 329743Authorship 349605Authorship 406996Authorship 1337969Authorship 1338821431658273Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JPPloS oneMeasurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.PLoS One2019-10-28T00:00:002019Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.31668825Klepin HD, Ritchie E, Major-Elechi B, Le-Rademacher J, Seisler D, Storrick L, Sanford BL, Marcucci G, Zhao W, Geyer SA, Ballman KV, Powell BL, Baer MR, Stock W, Cohen HJ, Stone RM, Larson RA, Uy GLJournal of geriatric oncologyGeriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020 01; 11(1):107-113.J Geriatr Oncol2019-10-24T00:00:002019Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).Authorship 302634Authorship 370897Authorship 296994Authorship 4157913Authorship 134162631680584Derman BA, Streck M, Wynne J, Christ TN, Curran E, Stock W, Knoebel RWLeukemia & lymphomaEfficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020 03; 61(3):614-622.Leuk Lymphoma2019-11-04T00:00:002019Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.Authorship 384663Authorship 421863Authorship 387771Authorship 392822Authorship 1342531831725894Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz ASBlood advancesResults from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.Blood Adv2019-11-26T00:00:002019Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.Authorship 394373Authorship 395792Authorship 388499Authorship 309171Authorship 433149Authorship 348022Authorship 134565331790983Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian HLeukemia researchImpact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.Leuk Res2019-11-25T00:00:002019Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.Authorship 3290910Authorship 415349Authorship 4436812Authorship 134951731869410Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani ASBlood advancesTherapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.Blood Adv2019-12-23T00:00:002019Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.Authorship 421177Authorship 443596Authorship 483358Authorship 135516631992847Kothari S, Artz AS, Lee SM, Fulton N, Park JH, Stock W, Larson RA, Odenike O, Kline J, LaBelle J, Kosuri S, Riedell P, Nakamura Y, Bishop MR, Liu HBone marrow transplantationDose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.Bone Marrow Transplant2020-01-28T00:00:002020Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.Authorship 341008Authorship 1356083Authorship 135644232018063Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu HBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationUnexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.Biol Blood Marrow Transplant2020-02-01T00:00:002020Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.32012214Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJBlood advancesLoncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 02 11; 4(3):449-457.Blood Adv2020-02-11T00:00:002020Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.Authorship 356541Authorship 357163Authorship 135818332048928Wang AY, Muffly LS, Stock WJCO oncology practicePhiladelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncol Pract. 2020 05; 16(5):231-238.JCO Oncol Pract2020-01-29T00:00:002020Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults.Authorship 394362Authorship 13594117Authorship 135865832074275Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike OBlood advancesA phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.Blood Adv2020-02-25T00:00:002020A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.32066543Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR, McNeer JL, Stock W, Stovall M, Krull KR, Sklar CA, Neglia JP, Armstrong GT, Oeffinger KC, Robison LL, Henderson TOThe Lancet. OncologyLate mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020 03; 21(3):421-435.Lancet Oncol2020-02-14T00:00:002020Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study.Authorship 390215Authorship 1360206Authorship 1360301132092139Marcucci G, Geyer S, Laumann K, Zhao W, Bucci D, Uy GL, Blum W, Eisfeld AK, Pardee TS, Wang ES, Stock W, Kolitz JE, Kohlschmidt J, Mrózek K, Bloomfield CD, Stone RM, Larson RABlood advancesCombination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020 02 25; 4(4):696-705.Blood Adv2020-02-25T00:00:002020Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.32097459King AA, Vesely SK, Vettese E, Cook S, Cuker A, Stock W, Homer M, Fritz J, Sung LBlood advancesImpact of gender and caregiving responsibilities on academic success in hematology. Blood Adv. 2020 02 25; 4(4):755-761.Blood Adv2020-02-25T00:00:002020Impact of gender and caregiving responsibilities on academic success in hematology.Authorship 3649714Authorship 394189Authorship 136399332170769Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BDAmerican journal of hematologyBortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020 06; 95(6):583-593.Am J Hematol2020-04-06T00:00:002020Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.Authorship 399821Authorship 390113Authorship 4163210Authorship 3954311Authorship 1370541432311140Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JGAmerican journal of hematologyA multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.Am J Hematol2020-05-08T00:00:002020A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.Authorship 403224Authorship 1371961032358888Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike OBritish journal of haematologyClinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.Br J Haematol2020-05-01T00:00:002020Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.Authorship 1373375Authorship 137339532376970Cooperrider JH, Fulton N, Artz AS, Larson RA, Stock W, Kosuri S, Bishop M, Liu HBone marrow transplantationPhase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206.Bone Marrow Transplant2020-05-06T00:00:002020Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.32378440Jabbour E, Stelljes M, Advani AS, DeAngelo DJ, Gökbuget N, Marks DI, Stock W, O'Brien S, Cassaday RD, Wang T, Neuhof A, Vandendries E, Kantarjian HLeukemia & lymphomaImpact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015.Leuk Lymphoma2020-05-07T00:00:002020Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.Authorship 98372Authorship 419418Authorship 4270512Authorship 493085Authorship 496094Authorship 1378992Authorship 13789343246451Thomas JA, Stock WAInternational journal of aging & human developmentThe concept of happiness: a multidimensional scaling investigation. Int J Aging Hum Dev. 1988; 27(2):141-54.Int J Aging Hum Dev1988-01-01T00:00:001988The concept of happiness: a multidimensional scaling investigation.32468488Patel AA, Thomas J, Rojek AE, Stock WCurrent treatment options in oncologyBiology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.Curr Treat Options Oncol2020-05-28T00:00:002020Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults.Authorship 436551Authorship 458301Authorship 4609518Authorship 4636314Authorship 477699Authorship 138258732521310Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh MLeukemia researchCamidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 08; 95:106385.Leuk Res2020-06-07T00:00:002020Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.Authorship 4881721Authorship 467892Authorship 4686711Authorship 139173132673388Stock WBloodThrombosis in ALL: a risk without clear mitigation. Blood. 2020 07 16; 136(3):264-265.Blood2020-07-16T00:00:002020Thrombosis in ALL: a risk without clear mitigation.Authorship 497029Authorship 139930532769965DeAngelo DJ, Advani AS, Marks DI, Stelljes M, Liedtke M, Stock W, Gökbuget N, Jabbour E, Merchant A, Wang T, Vandendries E, Neuhof A, Kantarjian H, O'Brien SBlood cancer journalInotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81.Blood Cancer J2020-08-07T00:00:002020Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.Authorship 1401581132805058Cassaday RD, Marks DI, DeAngelo DJ, Jabbour EJ, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes MBritish journal of haematologyImpact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.Br J Haematol2020-08-17T00:00:002020Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.Authorship 268862Authorship 2721813Authorship 2745917Authorship 1405002832885175Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, Coke CJ, Natarajan S, Khatamian A, Karol SE, Lopez-Lopez E, Diouf B, Smith C, Gocho Y, Hagiwara K, Roberts KG, Pounds S, Kornblau SM, Stock W, Paietta EM, Litzow MR, Inaba H, Mullighan CG, Jeha S, Pui CH, Cheng C, Savic D, Yu J, Gawad C, Relling MV, Yang JJ, Evans WENature cancerIntegrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nat Cancer. 2020 03; 1(3):329-344.Nat Cancer2020-03-09T00:00:002020Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.Authorship 352662Authorship 356055Authorship 363878Authorship 411822Authorship 140748332920736Prescott K, Jacobs M, Stock W, Wynne JCurrent hematologic malignancy reportsNew Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.Curr Hematol Malig Rep2020-12-01T00:00:002020New Approaches to Treating Challenging Subtypes of ALL in AYA Patients.Authorship 4744313Authorship 1410711232961375Flannelly C, Tan BE, Tan JL, McHugh CM, Sanapala C, Lagu T, Liesveld JL, Aljitawi O, Becker MW, Mendler JH, Klepin HD, Stock W, Wildes TM, Artz A, Majhail NS, Loh KPBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationBarriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. Biol Blood Marrow Transplant. 2020 12; 26(12):2335-2345.Biol Blood Marrow Transplant2020-09-20T00:00:002020Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.8516290Le Beau MM, Espinosa R, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CAProceedings of the National Academy of Sciences of the United States of AmericaCytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993 Jun 15; 90(12):5484-8.Proc Natl Acad Sci U S A1993-06-15T00:00:001993Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.8638610Nand S, Stock W, Godwin J, Fisher SGAmerican journal of hematologyLeukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996 May; 52(1):42-6.Am J Hematol1996-05-01T00:00:001996Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.8839861Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RABloodPolymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996 Oct 01; 88(7):2665-70.Blood1996-10-01T00:00:001996Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.Authorship 141325433038027Rank CU, Lynggaard LS, Als-Nielsen B, Stock W, Toft N, Nielsen OJ, Frandsen TL, Tuckuviene R, Schmiegelow KThe Cochrane database of systematic reviewsProphylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020 10 10; 10:CD013399.Cochrane Database Syst Rev2020-10-10T00:00:002020Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.Authorship 1414361233040623Loh KP, Abdallah M, Kadambi S, Wells M, Kumar AJ, Mendler JH, Liesveld JL, Wittink M, O'Dwyer K, Becker MW, McHugh C, Stock W, Majhail NS, Wildes TM, Duberstein P, Mohile SG, Klepin HDLeukemia & lymphomaTreatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. Leuk Lymphoma. 2021 02; 62(2):387-398.Leuk Lymphoma2020-10-11T00:00:002020Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists.1486800Stock W, Chandrasekharappa SC, Neuman WL, Le Beau MM, Brownstein BH, Westbrook CACytogenetics and cell geneticsCharacterization of yeast artificial chromosomes containing interleukin genes on human chromosome 5. Cytogenet Cell Genet. 1992; 61(4):263-5.Cytogenet Cell Genet1992-01-01T00:00:001992Characterization of yeast artificial chromosomes containing interleukin genes on human chromosome 5.10390187Wickrema A, Chen F, Namin F, Yi T, Ahmad S, Uddin S, Chen YH, Feldman L, Stock W, Hoffman R, Platanias LCExperimental hematologyDefective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999 Jul; 27(7):1124-32.Exp Hematol1999-07-01T00:00:001999Defective expression of the SHP-1 phosphatase in polycythemia vera.KoenVan BesienKoen Van Besien0.000000000000000.000000000000002944Van Besien, KoenPROFESSORAuthorship 141821933106665Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JCNature medicinePrecision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.Nat Med2020-10-26T00:00:002020Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.D018380Procedures1408780.592665Hematopoietic Stem Cell Transplantation11147224Stock W, Estrov ZHematology/oncology clinics of North AmericaStudies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix.Hematol Oncol Clin North Am2000-12-01T00:00:002000Studies of minimal residual disease in acute lymphocytic leukemia.11877308Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W, Maynard V, Jessop E, Peace D, Huml M, Thomason D, Chen YH, van Besien KBloodAllogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002 Mar 15; 99(6):2255-8.Blood2002-03-15T00:00:002002Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.Authorship 142125133231879Stock W, Martinelli G, Stelljes M, DeAngelo DJ, Gökbuget N, Advani AS, O'Brien S, Liedtke M, Merchant AA, Cassaday RD, Wang T, Zhang H, Vandendries E, Jabbour E, Marks DI, Kantarjian HMCancerEfficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913.Cancer2020-11-24T00:00:002020Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.Authorship 142438233256898Curran E, Stock WSeminars in hematologyEditorial. Semin Hematol. 2020 07; 57(3):101.Semin Hematol2020-07-01T00:00:002020Editorial.1706957Heimann PS, Vardiman JW, Stock W, Platanias LC, Golomb HMBloodCD5+, CD11c+, CD20+ hairy cell leukemia. Blood. 1991 Apr 01; 77(7):1617-9.Blood1991-04-01T00:00:001991CD5+, CD11c+, CD20+ hairy cell leukemia.11607768Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien KBone marrow transplantationFludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant. 2001 Sep; 28(6):557-62.Bone Marrow Transplant2001-09-01T00:00:002001Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.12145465Verma A, Stock W, Norohna S, Shah R, Bradlow B, Platanias LCActa haematologicaProgressive transformation of germinal centers. Report of 2 cases and review of the literature. Acta Haematol. 2002; 108(1):33-8.Acta Haematol2002-01-01T00:00:002002Progressive transformation of germinal centers. Report of 2 cases and review of the literature.12815472van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman JBone marrow transplantationSafety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13.Bone Marrow Transplant2003-07-01T00:00:002003Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.12942092Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Hoffman R, Sossman JBone marrow transplantationRegimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6.Bone Marrow Transplant2003-09-01T00:00:002003Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.15526015van Besien K, Artz A, Stock WLeukemiaUnrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia. 2005 Jan; 19(1):31-3.Leukemia2005-01-01T00:00:002005Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?12691141Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RALeukemia & lymphomaTreatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma. 2003 Jan; 44(1):39-48.Leuk Lymphoma2003-01-01T00:00:002003Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.Authorship 1435902333496745Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock WBlood advancesComparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.Blood Adv2021-01-26T00:00:002021Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.16400339Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien KBone marrow transplantationPre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.Bone Marrow Transplant2006-02-01T00:00:002006Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.Medicine-Hematology and Oncology15806131Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien KBone marrow transplantationImpact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70.Bone Marrow Transplant2005-05-01T00:00:002005Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.15824414Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol. 2005 May 20; 23(15):3404-11.J Clin Oncol2005-04-11T00:00:002005Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.16236241Wu D, Nair-Gill E, Sher DA, Parker LL, Campbell JM, Siddiqui M, Stock W, Kron SJAnalytical biochemistryAssaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. Anal Biochem. 2005 Dec 01; 347(1):67-76.Anal Biochem2005-09-22T00:00:002005Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.1911464Stock W, Lichtman S, Ratain MJ, O'Brein S, Vogelzang NJ, Van Echo DAAnnals of oncology : official journal of the European Society for Medical OncologyResponse to high dose cyclophosphamide with GM-CSF in Merkel cell tumor. Ann Oncol. 1991 Jul; 2(7):522-3.Ann Oncol1991-07-01T00:00:001991Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.Authorship 144096733559517Major A, Collins J, Craney C, Heitman AK, Bauer E, Zerante E, Stock W, Bishop MR, Jasielec JLeukemia & lymphomaManagement of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 07; 62(7):1765-1769.Leuk Lymphoma2021-02-09T00:00:002021Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.17124059Stock WHematology. American Society of Hematology. Education ProgramControversies in treatment of AML: case-based discussion. Hematology Am Soc Hematol Educ Program. 2006; 185-91.Hematology Am Soc Hematol Educ Program2006-01-01T00:00:002006Controversies in treatment of AML: case-based discussion.Authorship 1444992Authorship 1444822933602684Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Stelljes M, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani ASClinical cancer research : an official journal of the American Association for Cancer ResearchInotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.Clin Cancer Res2021-02-18T00:00:002021Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.33593877Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock WCancer discoveryVenetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 06; 11(6):1440-1453.Cancer Discov2021-02-16T00:00:002021Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.16477019Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PSProceedings of the National Academy of Sciences of the United States of AmericaGene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2794-9.Proc Natl Acad Sci U S A2006-02-13T00:00:002006Gene expression changes associated with progression and response in chronic myeloid leukemia.Authorship 1445673233637765Kennedy AL, Myers KC, Bowman J, Gibson CJ, Camarda ND, Furutani E, Muscato GM, Klein RH, Ballotti K, Liu S, Harris CE, Galvin A, Malsch M, Dale D, Gansner JM, Nakano TA, Bertuch A, Vlachos A, Lipton JM, Castillo P, Connelly J, Churpek J, Edwards JR, Hijiya N, Ho RH, Hofmann I, Huang JN, Keel S, Lamble A, Lau BW, Norkin M, Stieglitz E, Stock W, Walkovich K, Boettcher S, Brendel C, Fleming MD, Davies SM, Weller EA, Bahl C, Carter SL, Shimamura A, Lindsley RCNature communicationsDistinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021 02 26; 12(1):1334.Nat Commun2021-02-26T00:00:002021Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.18297531Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock WLeukemia & lymphomaSuccessful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.Leuk Lymphoma2008-03-01T00:00:002008Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.Authorship 1447721133658483Eisfelder BJ, Saygin C, Wynne J, Colton MW, Fischietti M, Beauchamp EM, Cheng JX, Odenike O, Roboz G, Alachkar H, Stock WBlood cancer journalOTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.Blood Cancer J2021-03-03T00:00:002021OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.18536580Larson S, Stock WCurrent opinion in hematologyProgress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol. 2008 Jul; 15(4):400-7.Curr Opin Hematol2008-07-01T00:00:002008Progress in the treatment of adults with acute lymphoblastic leukemia.15148492Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPhase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94.Biol Blood Marrow Transplant2004-06-01T00:00:002004Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.D015470Disorders1227550.629242Leukemia, Myeloid, Acute18413836Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci GClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9.Clin Cancer Res2008-04-15T00:00:002008A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.17846595Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien KBone marrow transplantationOutcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.Bone Marrow Transplant2007-09-10T00:00:002007Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.15155474Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock WBloodIrreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4.Blood2004-06-01T00:00:002004Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.18981008Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock WClinical cancer research : an official journal of the American Association for Cancer ResearchHistone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008 Nov 01; 14(21):7095-101.Clin Cancer Res2008-11-01T00:00:002008Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.18670778Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA, Cancer and Leukemia Group BCancer chemotherapy and pharmacologyA phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.Cancer Chemother Pharmacol2008-08-01T00:00:002008A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.19142796Poiré X, Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien KLeukemia & lymphomaAllogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.Leuk Lymphoma2009-01-01T00:00:002009Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.Authorship 145586233785862Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf DLeukemiaSuperior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 07; 35(7):2076-2085.Leukemia2021-03-30T00:00:002021Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.16920562Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, Zimmerman T, Smith S, Godley L, Thirman M, Daugherty C, Extermann M, Larson R, van Besien KBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPerformance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.Biol Blood Marrow Transplant2006-09-01T00:00:002006Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.20425459Mattison R, Stock WCurrent hematologic malignancy reportsApproaches to treatment for acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):144-51.Curr Hematol Malig Rep2008-07-01T00:00:002008Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.19645130Stock WClinical advances in hematology & oncology : H&OClinical trials in adult AML. Clin Adv Hematol Oncol. 2009 Jun; 7(6):8-10.Clin Adv Hematol Oncol2009-06-01T00:00:002009Clinical trials in adult AML.19521325Stock WClinical advances in hematology & oncology : H&OPediatric regimens for adult acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009 Apr; 7(4):244-6.Clin Adv Hematol Oncol2009-04-01T00:00:002009Pediatric regimens for adult acute lymphoblastic leukemia.19710500Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien SBloodPhase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33.Blood2009-08-26T00:00:002009Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.19825446Wetzler M, Stock WHematology/oncology clinics of North AmericaPreface: acute lymphoblastic leukemia--quo vadis? Hematol Oncol Clin North Am. 2009 Oct; 23(5):xi-xviii.Hematol Oncol Clin North Am2009-10-01T00:00:002009Preface: acute lymphoblastic leukemia--quo vadis?19778846Kenkre VP, Stock WClinical lymphoma & myelomaBurkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S231-8.Clin Lymphoma Myeloma2009-01-01T00:00:002009Burkitt lymphoma/leukemia: improving prognosis.20558311Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne ASBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211.Biol Blood Marrow Transplant2010-06-14T00:00:002010NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.20919852O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien KLeukemia & lymphomaPhase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.Leuk Lymphoma2010-10-04T00:00:002010Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.20208570Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock WBone marrow transplantationFeasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec; 45(12):1692-8.Bone Marrow Transplant2010-03-08T00:00:002010Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.19821799van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz ASLeukemia & lymphomaPatterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.Leuk Lymphoma2009-11-01T00:00:002009Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.20101737Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HMCancerAdult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010 Mar 01; 116(5):1165-76.Cancer2010-03-01T00:00:002010Adult acute lymphoblastic leukemia: concepts and strategies.20536346Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RALeukemia & lymphomaTreatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.Leuk Lymphoma2010-06-01T00:00:002010Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.17502895Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien KBone marrow transplantationChimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181.Bone Marrow Transplant2007-05-14T00:00:002007Chimerism does not predict for outcome after alemtuzumab based conditioning.20637879Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne ASBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationNCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46.Biol Blood Marrow Transplant2010-07-15T00:00:002010NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.20688393Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA, Cancer and Leukemia Group BLeukemia researchHigh dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33.Leuk Res2010-08-04T00:00:002010High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.20705755Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RABloodArsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11; 116(19):3751-7.Blood2010-08-12T00:00:002010Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.18217206Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock WInvestigational new drugsPhase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.Invest New Drugs2008-01-24T00:00:002008Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.17786717Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien KLeukemia & lymphomaSuccessful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805.Leuk Lymphoma2007-09-01T00:00:002007Successful allogeneic transplantation of patients with suspected prior invasive mold infection.21913806Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock WLeukemia & lymphomaHigh dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.Leuk Lymphoma2012-03-01T00:00:002012High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).21976674Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien KBloodReduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45.Blood2011-10-05T00:00:002011Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.19660716O'Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, Pursell K, Rich E, Stock W, van Besien KBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationBK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1.Biol Blood Marrow Transplant2009-07-09T00:00:002009BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants.21421110Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock WSeminars in oncologyGene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.Semin Oncol2011-04-01T00:00:002011Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?Authorship 146904234088982Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf DLeukemiaCorrection: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 Jul; 35(7):2140.Leukemia2021-07-01T00:00:002021Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.23032621Bleyer A, Siegel SE, Coccia PF, Stock W, Seibel NLJournal of clinical oncology : official journal of the American Society of Clinical OncologyChildren, adolescents, and young adults with leukemia: the empty half of the glass is growing. J Clin Oncol. 2012 Nov 10; 30(32):4037-8; author reply 4038-9.J Clin Oncol2012-10-01T00:00:002012Children, adolescents, and young adults with leukemia: the empty half of the glass is growing.22079470van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz ASBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPhase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.Biol Blood Marrow Transplant2011-11-09T00:00:002011Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.22102709Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, Hsi ED, Bucci DM, Linker CA, Cheson BD, Stock WHaematologicaDetection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85.Haematologica2011-11-18T00:00:002011Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.Authorship 1469944034103329Montefiori LE, Bendig S, Gu Z, Chen X, Pölönen P, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, Litzow MR, Rowe JM, den Boer ML, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CGCancer discoveryEnhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discov. 2021 11; 11(11):2846-2867.Cancer Discov2021-06-08T00:00:002021Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia.22915637Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJBloodA randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.Blood2012-08-22T00:00:002012A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.20001232Stock WLeukemia & lymphomaCurrent treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2010 Feb; 51(2):188-98.Leuk Lymphoma2010-02-01T00:00:002010Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.18940674Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA, van Besien KBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.Biol Blood Marrow Transplant2008-11-01T00:00:002008Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.15929100Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DG, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JEAmerican journal of hematologyDurable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol. 2005 Jun; 79(2):119-27.Am J Hematol2005-06-01T00:00:002005Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.AnandPatelAnand Patel41.7886000000000087.598699999999994043Patel, Anand0000-0002-0296-8686Assistant ProfessorAuthorship 14760725Authorship 1476151834156898Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyOpen-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 10 10; 39(29):3261-3272.J Clin Oncol2021-06-22T00:00:002021Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.34151288Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Ju B, Rowland L, Shi L, Maxwell D, Smart B, Crews KR, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Easton J, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJNature cancerNetwork-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 03; 2(3):284-299.Nat Cancer2021-01-21T00:00:002021Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.19556425Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KMBloodGranulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45.Blood2009-06-25T00:00:002009Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).19851858Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock WBreast cancer research and treatmentScreening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat. 2010 Jan; 119(2):391-8.Breast Cancer Res Treat2010-01-01T00:00:002010Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).Authorship 148038534251414Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mrózek K, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RABlood advancesPhase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787.Blood Adv2021-07-13T00:00:002021Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).34289383Chen D, Xia S, Zhang R, Li Y, Famulare CA, Fan H, Wu R, Wang M, Zhu AC, Elf SE, Su R, Dong L, Arellano M, Blum WG, Mao H, Lonial S, Stock W, Odenike O, Le Beau M, Boggon TJ, He C, Chen J, Gao X, Levine RL, Chen JMolecular cellLysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11.Mol Cell2021-07-20T00:00:002021Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.16522812Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JMBloodMonitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 01; 108(1):28-37.Blood2006-03-07T00:00:002006Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Authorship 1481941721421111Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MMSeminars in oncologyAn integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.Semin Oncol2011-04-01T00:00:002011An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.21827361Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer ALeukemia & lymphomaPrevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.Leuk Lymphoma2011-08-10T00:00:002011Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Authorship 148351634309634King AA, Vesely SK, Dadzie G, Calhoun C, Cuker A, Stock W, Walker A, Fritz J, Sung LBlood advancesSelf-reported positive impact of mentored clinical research training is associated with academic success in hematology. Blood Adv. 2021 07 27; 5(14):2919-2924.Blood Adv2021-07-27T00:00:002021Self-reported positive impact of mentored clinical research training is associated with academic success in hematology.23075701Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett WThe Lancet. OncologyOral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.Lancet Oncol2012-10-15T00:00:002012Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.21239766Stock WHematology. American Society of Hematology. Education ProgramAdolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:21-9.Hematology Am Soc Hematol Educ Program2010-01-01T00:00:002010Adolescents and young adults with acute lymphoblastic leukemia.Authorship 1490671334424946Zanetti C, Kumar R, Ender J, Godavarthy PS, Hartmann M, Hey J, Breuer K, Weissenberger ES, Minciacchi VR, Karantanou C, Gu Z, Roberts KG, Metzler M, Stock W, Mullighan CG, Bloomfield CD, Filmann N, Bankov K, Hartmann S, Hasserjian RP, Cousins AF, Halsey C, Plass C, Lipka DB, Krause DSBloodThe age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood. 2021 11 11; 138(19):1870-1884.Blood2021-11-11T00:00:002021The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.Authorship 149563434473244Hantel A, Luskin MR, Garcia JS, Stock W, DeAngelo DJ, Abel GABlood advancesRacial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv. 2021 11 09; 5(21):4352-4360.Blood Adv2021-11-09T00:00:002021Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials.22280537Wang ES, Yee K, Koh LP, Hogge D, Enschede S, Carlson DM, Dudley M, Glaser K, McKeegan E, Albert DH, Li X, Pradhan R, Stock WLeukemia & lymphomaPhase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leuk Lymphoma. 2012 Aug; 53(8):1543-51.Leuk Lymphoma2012-03-01T00:00:002012Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.Authorship 149621834492682Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine S, Stone RM, Larson RABlood advancesDasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Adv. 2021 11 23; 5(22):4691-4700.Blood Adv2021-11-23T00:00:002021Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.7967737Stock W, Thirman MJ, Dodge RK, Rowley JD, Diaz MO, Wurster-Hill D, Sobol RE, Davey FR, Larson RA, Westbrook CALeukemiaDetection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study. Leukemia. 1994 Nov; 8(11):1918-22.Leukemia1994-11-01T00:00:001994Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study.Authorship 149734334511319Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis IClinical lymphoma, myeloma & leukemiaSOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):725-733.Clin Lymphoma Myeloma Leuk2021-07-16T00:00:002021SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.7885042Joventino LP, Stock W, Lane NJ, Daly KM, Mick R, Le Beau MM, Larson RALeukemiaCertain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995 Mar; 9(3):433-9.Leukemia1995-03-01T00:00:001995Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.18502832Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J, Children's Cancer Group, Cancer and Leukemia Group B studiesBloodWhat determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54.Blood2008-05-23T00:00:002008What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.18654114Stock WClinical advances in hematology & oncology : H&OAdvances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2008 Jul; 6(7):487-8.Clin Adv Hematol Oncol2008-07-01T00:00:002008Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.8094890Spielberger RT, Stock W, Larson RAThe New England journal of medicineListeriosis after 2-chlorodeoxyadenosine treatment. N Engl J Med. 1993 Mar 18; 328(11):813-4.N Engl J Med1993-03-18T00:00:001993Listeriosis after 2-chlorodeoxyadenosine treatment.19825455Abutalib SA, Wetzler M, Stock WHematology/oncology clinics of North AmericaLooking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct; 23(5):1099-119, vii.Hematol Oncol Clin North Am2009-10-01T00:00:002009Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.19860603Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JCLeukemia & lymphomaA phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec; 50(12):1958-63.Leuk Lymphoma2009-12-01T00:00:002009A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.19917845Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GPJournal of clinical oncology : official journal of the American Society of Clinical OncologyImmunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8.J Clin Oncol2009-11-16T00:00:002009Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.20522709Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA, Cancer and Leukemia Group BBloodP-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.Blood2010-06-03T00:00:002010P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.12732890Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, van Besien KBone marrow transplantationLow incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant. 2003 May; 31(9):813-6.Bone Marrow Transplant2003-05-01T00:00:002003Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.15124691Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JCAnnals of hematologyG3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol. 2004; 83 Suppl 1:S93-4.Ann Hematol2004-01-01T00:00:002004G3139, a BCL-2 antisense oligo-nucleotide, in AML.15570084Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TFJournal of clinical oncology : official journal of the American Society of Clinical OncologyDose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.J Clin Oncol2004-12-01T00:00:002004Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.16009946van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock WJournal of clinical oncology : official journal of the American Society of Clinical OncologyFludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.J Clin Oncol2005-07-11T00:00:002005Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.16224407Stock WClinical advances in hematology & oncology : H&OMinimal residual disease: current status in leukemia. Clin Adv Hematol Oncol. 2003 Apr; 1(4):210-1.Clin Adv Hematol Oncol2003-04-01T00:00:002003Minimal residual disease: current status in leukemia.16596225Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CDInternational journal of oncologyQuantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May; 28(5):1099-103.Int J Oncol2006-05-01T00:00:002006Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.16730060Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci GLeukemia researchA Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006 Jul; 30(7):777-83.Leuk Res2006-05-26T00:00:002006A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.Authorship 1506882634716350Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhäuser M, Röllig C, Altmann H, Ruhnke L, Kunadt D, Wagenführ L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gómez-Seguí I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsán S, Bödör C, Stölzel F, Onel K, Allan JMNature communicationsGenome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nat Commun. 2021 10 29; 12(1):6233.Nat Commun2021-10-29T00:00:002021Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.18425419Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJInvestigational new drugsA phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.Invest New Drugs2008-04-19T00:00:002008A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.18451242Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJClinical cancer research : an official journal of the American Association for Cancer ResearchA phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62.Clin Cancer Res2008-05-01T00:00:002008A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.18640578Dew A, Collins D, Artz A, Rich E, Stock W, Swanson K, van Besien KBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPaucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. Biol Blood Marrow Transplant. 2008 Aug; 14(8):938-41.Biol Blood Marrow Transplant2008-08-01T00:00:002008Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.19708032Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien SCancerPhase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009 Dec 01; 115(23):5490-8.Cancer2009-12-01T00:00:002009Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.21142785Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien KLeukemia & lymphomaT-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.Leuk Lymphoma2010-12-10T00:00:002010T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.21494838Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden MInvestigational new drugsPhase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1107-15.Invest New Drugs2011-04-15T00:00:002011Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.22378655Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi SPediatric blood & cancerFLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7.Pediatr Blood Cancer2012-02-29T00:00:002012FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.22548695Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz ASCytotherapyInfluence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.Cytotherapy2012-05-02T00:00:002012Influence of related donor age on outcomes after peripheral blood stem cell transplantation.22734072Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock WBloodTreatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108.Blood2012-06-25T00:00:002012Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.Authorship 15194826Authorship 1518631334981142Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock WAnnals of hematologyPhase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022 Mar; 101(3):557-569.Ann Hematol2022-01-04T00:00:002022Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.34983928Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhäuser M, Röllig C, Altmann H, Ruhnke L, Kunadt D, Wagenführ L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gómez-Seguí I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsán S, Bödör C, Stölzel F, Onel K, Allan JMNature communicationsAuthor Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nat Commun. 2022 Jan 04; 13(1):2.Nat Commun2022-01-04T00:00:002022Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.Authorship 152189235031177Douer D, Gökbuget N, Stock W, Boissel NBlood reviewsOptimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022 05; 53:100908.Blood Rev2021-11-12T00:00:002021Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.Authorship 1523242135061876Abraham IE, Rauscher GH, Patel AA, Pearse WB, Rajakumar P, Burkart M, Aleem A, Dave A, Bharadwaj S, Paydary K, Acevedo-Mendez M, Goparaju K, Gomez R, Carlson K, Tsai SB, Quigley JG, Galvin JP, Zia M, Larson ML, Berg S, Stock W, Altman JK, Khan IBloodStructural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226.Blood2022-04-07T00:00:002022Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.Authorship 15315411Authorship 15332311Authorship 153338735157496Advani AS, Moseley A, O'Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic RB, Baer MR, Stock W, Bhave RR, Othus M, Harvey RC, Willman CL, Litzow MR, Stone RM, Sharon E, Erba HPJournal of clinical oncology : official journal of the American Society of Clinical OncologySWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582.J Clin Oncol2022-02-14T00:00:002022SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.35171727Kaumeyer B, Fidai S, Sukhanova M, Yap KL, Segal J, Raca G, Stock W, McNeer J, Lager AM, Gurbuxani SLeukemia & lymphomaMUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444.Leuk Lymphoma2022-02-16T00:00:002022MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia.35192684Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, Litzow M, Rowe JM, Luger SM, Hunger SP, Ryland GL, Schmidt B, Ekert PG, Oshlack A, Grimmond SM, Rehn J, Breen J, Yeung D, White DL, Aldoss I, Jabbour EJ, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady S, Zhang J, Roberts KG, Blombery P, Mullighan CGBloodEnhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022 06 16; 139(24):3519-3531.Blood2022-06-16T00:00:002022Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.Authorship 1538131335349669Epstein-Peterson ZD, Derkach A, Geyer S, Mrózek K, Kohlschmidt J, Park JH, Rajeeve S, Stein EM, Zhang Y, Iland H, Campbell LJ, Larson RA, Poiré X, Powell BL, Stock W, Stone RM, Tallman MSBlood advancesEffect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Adv. 2022 06 14; 6(11):3433-3439.Blood Adv2022-06-14T00:00:002022Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.Authorship 154100535380890DuVall AS, Sheade J, Anderson D, Yates SJ, Stock WJCO oncology practiceUpdates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! JCO Oncol Pract. 2022 07; 18(7):479-487.JCO Oncol Pract2022-04-05T00:00:002022Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!Authorship 1547951335590059Hetzel S, Mattei AL, Kretzmer H, Qu C, Chen X, Fan Y, Wu G, Roberts KG, Luger S, Litzow M, Rowe J, Paietta E, Stock W, Mardis ER, Wilson RK, Downing JR, Mullighan CG, Meissner ANature cancerAcute lymphoblastic leukemia displays a distinct highly methylated genome. Nat Cancer. 2022 06; 3(6):768-782.Nat Cancer2022-05-19T00:00:002022Acute lymphoblastic leukemia displays a distinct highly methylated genome.Authorship 1552275Authorship 1552541835671062Ferguson DC, McCorkle JR, Barnett KR, Bonten EJ, Bergeron BP, Bhattarai KR, Yang W, Smith C, Hansen BS, Bajpai R, Dong Q, Autry RJ, Gocho Y, Diedrich JD, Crews KR, Pruett-Miller SM, Roberts KG, Stock W, Mullighan CG, Inaba H, Jeha S, Pui CH, Yang JJ, Relling MV, Evans WE, Savic DBlood advancesAmino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Adv. 2022 06 14; 6(11):3386-3397.Blood Adv2022-06-14T00:00:002022Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia.35658244Wu S, Wang M, Alqahtani A, Lou M, Stock W, Bhojwani D, Alachkar HBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapieHispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia. Biomed Pharmacother. 2022 Jun; 150:113000.Biomed Pharmacother2022-04-29T00:00:002022Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.Authorship 155300435696629Hantel A, Kohlschmidt J, Eisfeld AK, Stock W, Jacobson S, Mandrekar S, Larson RA, Stone RM, Lathan CS, DeAngelo DJ, Byrd JC, Abel GAJournal of clinical oncology : official journal of the American Society of Clinical OncologyInequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718.J Clin Oncol2022-06-13T00:00:002022Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.Authorship 1553982Authorship 155448335727422Maristany S, DuVall AS, Stock W, Adeleye AJJournal of assisted reproduction and geneticsPrimary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. J Assist Reprod Genet. 2022 Aug; 39(8):1733-1738.J Assist Reprod Genet2022-06-21T00:00:002022Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.35728059Anderson DR, Stock W, Karrison TG, Leader ABlood advancesD-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2022 09 13; 6(17):5146-5151.Blood Adv2022-09-13T00:00:002022D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia.Authorship 1558054735767897Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi ABloodInternational Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.Blood2022-09-15T00:00:002022International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.Authorship 1561221535838753Muffly L, Yin J, Jacobson S, Wall A, Quiroz E, Advani AS, Luger SM, Tallman MS, Litzow MR, Foster MC, Erba HP, Appelbaum FR, Larson RA, Keegan THM, Stock WBlood advancesDisparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.Blood Adv2022-07-26T00:00:002022Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.35844676Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock WEJHaemEfficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021 Aug; 2(3):413-420.EJHaem2021-06-22T00:00:002021Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults.Authorship 15614914Authorship 156171635851593Tran MC, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum R, Bishop MR, Aydogan B, Liu HBlood advancesA phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.Blood Adv2023-02-14T00:00:002023A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.36240471Alban J, DuVall A, Gurbuxani S, Stock W, Patel AAJCO precision oncologyOutcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.JCO Precis Oncol2022-10-01T00:00:002022Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.D054198Disorders723690.731498Precursor Cell Lymphoblastic Leukemia-Lymphoma36655425Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MWHaematologicaClinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.Haematologica2023-08-01T00:00:002023Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.Authorship 1580352Authorship 1580373Authorship 1580393Authorship 1580423Authorship 1580473Authorship 1580492Authorship 1580533Authorship 1581067Authorship 15810744Authorship 1581171Authorship 1581184Authorship 1581194Authorship 1581203Authorship 1581213Authorship 1581232Authorship 1581253Authorship 1581262Authorship 1581323Authorship 1581352Authorship 15815615Authorship 1581653Authorship 15817344Authorship 1583108Authorship 1580382Authorship 1580407Authorship 1580413Authorship 1580441Authorship 1580463Authorship 1580482Authorship 1580542Authorship 1580557Authorship 1580562Authorship 1580743Authorship 15809510Authorship 1581223Authorship 1599016Authorship 1580334Authorship 1580431Authorship 1581332Authorship 1599646Authorship 1581243Authorship 1581293Authorship 1581304Authorship 1581342Authorship 1581414Authorship 1581477Authorship 1583794Authorship 1590994Authorship 1591823Authorship 15925514Authorship 15970671479855Graupe F, Schwenk W, Hucke HP, Stock WLangenbecks Archiv fur Chirurgie[Inguinal hernia repair modified by Kirschner. A critical analysis after 11 years of clinical experience]. Langenbecks Arch Chir. 1992; 377(6):324-31.Langenbecks Arch Chir1992-01-01T00:00:001992[Inguinal hernia repair modified by Kirschner. A critical analysis after 11 years of clinical experience].1730200Schwenk W, Hucke HP, Stock WDeutsche medizinische Wochenschrift (1946)[Postoperative complications of elective resection of the colon in diverticulitis]. Dtsch Med Wochenschr. 1992 Jan 10; 117(2):41-5.Dtsch Med Wochenschr1992-01-10T00:00:001992[Postoperative complications of elective resection of the colon in diverticulitis].2056845Böhm B, Nouchirvani K, Hucke HP, Stock WLangenbecks Archiv fur Chirurgie[Morbidity and mortality after elective resections of colorectal cancers]. Langenbecks Arch Chir. 1991; 376(2):93-101.Langenbecks Arch Chir1991-01-01T00:00:001991[Morbidity and mortality after elective resections of colorectal cancers].7634944Schwenk W, Hucke HP, Graupe F, Stock WDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen[Is the surgeon a prognostically relevant factor after R0-resection of colorectal carcinoma?]. Chirurg. 1995 Apr; 66(4):334-42; discussion 342-3.Chirurg1995-04-01T00:00:001995[Is the surgeon a prognostically relevant factor after R0-resection of colorectal carcinoma?].7941112Schwenk W, Eyssel M, Badke A, Hucke HP, Stock WUnfallchirurgie[Risk analysis of primary endoprosthetic management of proximal femur fractures]. Unfallchirurgie. 1994 Aug; 20(4):216-22.Unfallchirurgie1994-08-01T00:00:001994[Risk analysis of primary endoprosthetic management of proximal femur fractures].8449134Böhm B, Schwenk W, Hucke HP, Stock WDiseases of the colon and rectumDoes methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 1993 Mar; 36(3):280-6.Dis Colon Rectum1993-03-01T00:00:001993Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma?9101902Hansen O, Zarras K, Graupe F, Stock WLangenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress[Surgical therapy of sigmoid diverticulitis in elderly patients.--What decides against early elective resection]. Langenbecks Arch Chir Suppl Kongressbd. 1996; 113:470-3.Langenbecks Arch Chir Suppl Kongressbd1996-01-01T00:00:001996[Surgical therapy of sigmoid diverticulitis in elderly patients.--What decides against early elective resection].8867345Hansen O, Zarras K, Graupe F, Dellana M, Stock WZentralblatt fur Chirurgie[Surgical treatment of diverticulitis of the large intestine--a plea for early elective resection]. Zentralbl Chir. 1996; 121(3):190-200.Zentralbl Chir1996-01-01T00:00:001996[Surgical treatment of diverticulitis of the large intestine--a plea for early elective resection].9574235Graupe F, Hansen O, Stock WLangenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress[Value of individually risk-adjusted after-care--economic management of oncologic effectiveness?]. Langenbecks Arch Chir Suppl Kongressbd. 1997; 114:665-8.Langenbecks Arch Chir Suppl Kongressbd1997-01-01T00:00:001997[Value of individually risk-adjusted after-care--economic management of oncologic effectiveness?].9576203Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany RBritish journal of haematologyA phase II trial of interleukin-2 in myelodysplastic syndromes. Br J Haematol. 1998 Apr; 101(1):205-7.Br J Haematol1998-04-01T00:00:001998A phase II trial of interleukin-2 in myelodysplastic syndromes.10880055Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MAThe Journal of clinical investigationPotential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 2000 Jul; 106(1):117-24.J Clin Invest2000-07-01T00:00:002000Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.26407235Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, Aster JC, Kuo F, Huang D, Lira PD, McLachlan KR, Kern KA, Garcia-Manero G, Martinelli GBlood cancer journalA Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350.Blood Cancer J2015-09-25T00:00:002015A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.36453516Saygin C, Cannova J, Stock W, Muffly LHaematologicaMeasurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022 Dec 01; 107(12):2783-2793.Haematologica2022-12-01T00:00:002022Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.36269846Aldoss I, Yin J, Wall A, Mrózek K, Liedtke M, Claxton DF, Foster MC, Appelbaum FR, Erba HP, Litzow MR, Tallman MS, Stone RM, Larson RA, Advani AS, Stock W, Luger SMBlood advancesThe impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 01 24; 7(2):196-204.Blood Adv2023-01-24T00:00:002023The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.1479867Schwenk W, Böhm B, Badke A, Zarras K, Stock WLeber, Magen, Darm[Preoperative esophagogastroduodenoscopy before elective surgical therapy of symptomatic cholelithiasis]. Leber Magen Darm. 1992 Nov; 22(6):225-9.Leber Magen Darm1992-11-01T00:00:001992[Preoperative esophagogastroduodenoscopy before elective surgical therapy of symptomatic cholelithiasis].1625508Graupe F, Böhm B, Hucke HP, Stock WLeber, Magen, Darm[Preoperative hemodilution before elective resections of colorectal cancers for sparing homologous blood transfusion]. Leber Magen Darm. 1992 May; 22(3):111-5.Leber Magen Darm1992-05-01T00:00:001992[Preoperative hemodilution before elective resections of colorectal cancers for sparing homologous blood transfusion].1645429Böhm B, Osswald J, Stock WLeber, Magen, Darm[Follow-up in stomach carcinoma]. Leber Magen Darm. 1991 Mar; 21(2):68, 71-4.Leber Magen Darm1991-03-01T00:00:001991[Follow-up in stomach carcinoma].1723133Böhm B, Osswald J, Hucke HP, Stock WLangenbecks Archiv fur Chirurgie[Individual risk-related after-care in colorectal cancer?]. Langenbecks Arch Chir. 1991; 376(6):314-22.Langenbecks Arch Chir1991-01-01T00:00:001991[Individual risk-related after-care in colorectal cancer?].2233589Böhm B, Nouchirvani K, Hucke HP, Stock WMedizinische Klinik (Munich, Germany : 1983)[The effect of age and sex on localization, tumor stage and prognosis of colorectal carcinoma]. Med Klin (Munich). 1990 Oct 15; 85(10):586-90.Med Klin (Munich)1990-10-15T00:00:001990[The effect of age and sex on localization, tumor stage and prognosis of colorectal carcinoma].2286800Dresing K, Stock WInternational journal of colorectal diseaseUltrasonic endoluminal examination in the follow-up of colorectal cancer. Initial experience and results. Int J Colorectal Dis. 1990 Dec; 5(4):188-94.Int J Colorectal Dis1990-12-01T00:00:001990Ultrasonic endoluminal examination in the follow-up of colorectal cancer. Initial experience and results.4042758Rassek D, Straub D, Sons HU, Stock WDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen[Results of the surgical treatment of gallbladder carcinomas]. Chirurg. 1985 Jul; 56(7):440-4.Chirurg1985-07-01T00:00:001985[Results of the surgical treatment of gallbladder carcinomas].6117812Ingianni G, Biemer E, Stock WMinerva chirurgica[Reimplantation of peripheral parts of the extremities. 808 cases and functional results]. Minerva Chir. 1981 Oct 31; 36(20):1337-44.Minerva Chir1981-10-31T00:00:001981[Reimplantation of peripheral parts of the extremities. 808 cases and functional results].7067540Stock W, Nitzschke E, Mackrodt HGDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen[Rational EDP-basic documentation in the surgical clinic]. Chirurg. 1982 Mar; 53(3):176-83.Chirurg1982-03-01T00:00:001982[Rational EDP-basic documentation in the surgical clinic].7513545Riggins GJ, Sherman SL, Phillips CN, Stock W, Westbrook CA, Warren STGenes, chromosomes & cancerCGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome. Genes Chromosomes Cancer. 1994 Feb; 9(2):141-4.Genes Chromosomes Cancer1994-02-01T00:00:001994CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome.8582169Graupe F, Schwenk W, Mackrodt HG, Stock WDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen[Acceptance and effectiveness of surgical vascular consultation--is it worthwhile?]. Chirurg. 1995 Dec; 66(12):1239-44; discussion 1245-6.Chirurg1995-12-01T00:00:001995[Acceptance and effectiveness of surgical vascular consultation--is it worthwhile?].8767088Graupe F, Schwenk W, Bracht B, Kröner-Herwig B, Stock WDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen[Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas]. Chirurg. 1996 Jun; 67(6):604-9; discussion 609-10.Chirurg1996-06-01T00:00:001996[Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas].8165960Schwenk W, Eyssel M, Badke A, Stock WAktuelle Traumatologie[Results of management of pertrochanteric comminuted fractures in the elderly with a tumor shaft endoprostheses]. Aktuelle Traumatol. 1994 Feb; 24(1):6-11.Aktuelle Traumatol1994-02-01T00:00:001994[Results of management of pertrochanteric comminuted fractures in the elderly with a tumor shaft endoprostheses].8413048Schwenk W, Osswald J, Huppa C, Stock WMedizinische Klinik (Munich, Germany : 1983)[Results of regular follow-up after removal of colorectal adenomas]. Med Klin (Munich). 1993 Aug 15; 88(8):471-7.Med Klin (Munich)1993-08-15T00:00:001993[Results of regular follow-up after removal of colorectal adenomas].8547862Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender JBone marrow transplantationA phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Bone Marrow Transplant. 1995 Nov; 16(5):655-61.Bone Marrow Transplant1995-11-01T00:00:001995A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.9132384Stock W, Mäurer J, Felix RDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete[Characteristics of normal cross-sectional anatomy of the skin in high resolution magnetic resonance tomography]. Hautarzt. 1997 Jan; 48(1):26-30.Hautarzt1997-01-01T00:00:001997[Characteristics of normal cross-sectional anatomy of the skin in high resolution magnetic resonance tomography].9612631Hansen O, Graupe F, Stock WDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen[Prognostic factors in perforating diverticulitis of the large intestine]. Chirurg. 1998 Apr; 69(4):443-9.Chirurg1998-04-01T00:00:001998[Prognostic factors in perforating diverticulitis of the large intestine].10873271Kaiser T, Gudat P, Stock W, Pappert G, Grol M, Neumeier D, Luppa PBAnalytical biochemistryBiotinylated steroid derivatives as ligands for biospecific interaction analysis with monoclonal antibodies using immunosensor devices. Anal Biochem. 2000 Jul 01; 282(2):173-85.Anal Biochem2000-07-01T00:00:002000Biotinylated steroid derivatives as ligands for biospecific interaction analysis with monoclonal antibodies using immunosensor devices.28218238Wolfson J, Sun CL, Wyatt L, Stock W, Bhatia SLeukemiaImpact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma. Leukemia. 2017 06; 31(6):1450-1453.Leukemia2017-02-20T00:00:002017Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.35973200Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz A, Riedell PA, Stock W, Karrison T, Fitzpatrick C, Venkataraman G, Cooper A, Smith SM, Bishop MR, Kline JBlood advancesPembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.Blood Adv2023-03-28T00:00:002023Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.36315007Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JMBlood advancesPevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363.Blood Adv2023-06-13T00:00:002023Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.36691748Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, Stock W, Jabbour EJAmerican journal of hematologySequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.Am J Hematol2023-02-06T00:00:002023Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.3677893Schweiberer L, Richter-Turtur M, Stock W, Wilker D, Geissler KDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen[Surgical treatment of large thoracic wall recurrences in breast cancer]. Chirurg. 1987 Sep; 58(9):607-11.Chirurg1987-09-01T00:00:001987[Surgical treatment of large thoracic wall recurrences in breast cancer].7498837Stock W, Lewan U, Dielert E, Umbricht-Sprüngli RE, Helaly PHandchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...[Long-term outcome of the donor site after free, microvascular pedicled iliac crest transplantation: experiences with 95 cases]. Handchir Mikrochir Plast Chir. 1995 Sep; 27(5):233-41.Handchir Mikrochir Plast Chir1995-09-01T00:00:001995[Long-term outcome of the donor site after free, microvascular pedicled iliac crest transplantation: experiences with 95 cases].Authorship 1610311536798219Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic DmedRxiv : the preprint server for health sciencesFunctional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. medRxiv. 2023 Feb 11.medRxiv2023-02-11T00:00:002023Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.Authorship 16119316Authorship 1612011336823396Mrózek K, Kohlschmidt J, Blachly JS, Nicolet D, Carroll AJ, Archer KJ, Mims AS, Larkin KT, Orwick S, Oakes CC, Kolitz JE, Powell BL, Blum WG, Marcucci G, Baer MR, Uy GL, Stock W, Byrd JC, Eisfeld AKLeukemiaOutcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023 04; 37(4):788-798.Leukemia2023-02-23T00:00:002023Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.36824825Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Yang JJ, Evans WE, Savic DbioRxiv : the preprint server for biologyEpigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures. bioRxiv. 2023 Jul 13.bioRxiv2023-07-13T00:00:002023Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures.http://www.pgrn.org/pgx-of-chemotherapeutic-toxicities.htmlMy Lab Objectivesanand_88_patel24178622Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike OClinical cancer research : an official journal of the American Association for Cancer ResearchPhase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.Clin Cancer Res2013-10-31T00:00:002013Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Authorship 1619425Authorship 16196712Authorship 1622497Authorship 1630877Authorship 163212637163059Parriott G, Hegermiller E, Morman RE, Frank C, Saygin C, Stock W, Bartom ET, Kee BLbioRxiv : the preprint server for biologyLoss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia. bioRxiv. 2023 Apr 25.bioRxiv2023-04-25T00:00:002023Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia.36939221Vesely SK, King A, Vettese E, Heller JG, Cuker A, Calhoun C, Stock W, Homer M, Fritz J, Sung LBlood advancesInfluence of participant and reviewer characteristics in application scores for a hematology research training program. Blood Adv. 2023 08 08; 7(15):4064-4071.Blood Adv2023-08-08T00:00:002023Influence of participant and reviewer characteristics in application scores for a hematology research training program.37058684Bhatt VR, Ulrich AM, Uy GL, Stone RM, Stock W, Ojelabi MO, Yin J, Kohlschmidt J, Eisfeld AK, Baer MR, Chow S, Klepin H, Le-Rademacher J, Jatoi AJCO oncology practiceOutcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials. JCO Oncol Pract. 2023 06; 19(6):e877-e891.JCO Oncol Pract2023-04-14T00:00:002023Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials.37076694Yoshimura S, Panetta JC, Hu J, Li L, Gocho Y, Du G, Umezawa A, Karol SE, Pui CH, Mullighan CG, Konopleva M, Stock W, Teachey DT, Jain N, Yang JJLeukemiaPreclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023 06; 37(6):1194-1203.Leukemia2023-04-19T00:00:002023Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.37078412Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MMCancerEntospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320.Cancer2023-04-20T00:00:002023Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.37363966Saygin C, Giordano G, Shimamoto K, Eisfelder B, Thomas-Toth A, Venkataraman G, Ananthanarayanan V, Vincent TL, DuVall A, Patel AA, Chen Y, Tan F, Anthony SP, Chen Y, Shen Y, Odenike O, Teachey DT, Kee BL, LaBelle J, Stock WClinical cancer research : an official journal of the American Association for Cancer ResearchDual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.Clin Cancer Res2023-08-15T00:00:002023Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.CanerSayginCaner Saygin41.7886000000000087.598699999999994321Saygin, CanerAssistant ProfessorAuthorship 1637208Authorship 1637589Authorship 16386920Authorship 1639136Authorship 1639387Authorship 1637881437271891Liang G, Wang L, You Q, Cahill K, Chen C, Zhang W, Fulton N, Stock W, Odenike O, He C, Han DAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Adv Sci (Weinh). 2023 08; 10(23):e2300445.Adv Sci (Weinh)2023-06-04T00:00:002023Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.37307212Rangel-Patiño J, Lee-Tsai YL, Urbalejo-Ceniceros VI, Luna-Perez MEM, Espinosa-Bautista KA, Amador LF, Cabrera-García Á, Balderas-Delgado C, Inclan-Alarcon SI, Neme-Yunes Y, Sanchez-Albarrán JM, Apodaca EI, Meillon-García L, Stock W, Demichelis-Gómez RBlood advancesA modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209.Blood Adv2023-09-26T00:00:002023A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America.37410014Alqahtani A, Alhousari D, Ali A, Yaghmour G, Orgel E, Curran E, Stock W, Bhojwani D, Alachkar HExpert opinion on drug metabolism & toxicologyAsparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding. Expert Opin Drug Metab Toxicol. 2023 Jan-Jun; 19(6):357-366.Expert Opin Drug Metab Toxicol2023-01-01T00:00:002023Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.37289505Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JCBlood advancesFramework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 Aug 22; 7(16):4671-4675.Blood Adv2023-08-22T00:00:002023Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.37397374Gallardo-Pérez MM, Gale RP, Reyes-Cisneros OA, Sánchez-Bonilla D, Fernández-Gutiérrez JA, Stock W, Murrieta-Álvarez I, Olivares-Gazca JC, Ruiz-Delgado GJ, Fonseca R, Ruiz-Argüelles GJFrontiers in oncologyTherapy of childhood acute lymphoblastic leukemia in resource-poor geospaces. Front Oncol. 2023; 13:1187268.Front Oncol2023-06-16T00:00:002023Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces.37459200Borate U, Yang F, Press R, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick DC, Juckett L, Norris B, Bucy T, Burd A, Stein EM, Patel P, Baer MR, Stock W, Schiller G, Blum W, Kovacsovics T, Litzow M, Foran J, Heerema NA, Rosenberg L, Marcus S, Yocum A, Stefanos M, Druker B, Byrd JC, Levine RL, Mims ABlood advancesSamples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood Adv. 2023 10 24; 7(20):6048-6054.Blood Adv2023-10-24T00:00:002023Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.Authorship 16446017MedicinePathologyUniversity of ChicagoLucyGodley22VmD60QeczMknJtY0fp/Cv/+94=Lucy Godley41.78927490000000-87.601250000000001017Godley, LucyProfessorRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professor37647601Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, Yilmaz M, Kantarjian H, Odenike O, Patel A, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims ABlood advancesPhase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.Blood Adv2023-11-14T00:00:002023Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.37575398Rowland L, Smart B, Brown A, Dettorre GM, Gocho Y, Hunt J, Yang W, Yoshimura S, Reyes N, Du G, John A, Maxwell D, Stock W, Kornblau S, Relling MV, Inaba H, Pui CH, Bourquin JP, Karol SE, Mullighan CG, Evans WE, Yang JJ, Crews KRBio-protocolEx vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells. Bio Protoc. 2023 Aug 05; 13(15):e4731.Bio Protoc2023-08-05T00:00:002023Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells.37603350Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JCBlood advancesFramework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 08 22; 7(16):4671-4675.Blood Adv2023-08-22T00:00:002023Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.Authorship 16603413Authorship 1659174Authorship 1660819Mark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.Professor19.57480.00426984887research areas6.921390.022532282coauthor of628.05441.800360similar to11351selected publicationsAndrzejJakubowiak1mhjCqp1G+POmHtvQFPt+2z5/syyp7BaZQ==Andrzej Jakubowiak41.78927490000000-87.601250000000002384Jakubowiak, AndrzejProfessorMary EileenDolan2mdtBK0UF8zMknJtY0fp/Cv/+94=Mary Eileen Dolan41.78927490000000-87.601250000000002594Dolan, Mary EileenProfessorAmitthaWickrema1nVgCKoHHOHYsW9naE/t8mL1sc65/A==Amittha Wickrema41.78927490000000-87.60125000000000318Wickrema, AmitthaProfessorOlatoyosiOdenikew21tDq8cEun5hHlsaUXv9Gq0+s+oOlatoyosi Odenike41.78927490000000-87.60125000000000399Odenike, OlatoyosiProfessorPeter H.O'DonnellPeter H. O'Donnell41.78927490000000-87.60125000000000537O'Donnell, Peter H.Associate ProfessorAuthorship 16774610Authorship 1678291137871309Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EMBlood advancesA study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440.Blood Adv2024-01-23T00:00:002024A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.37916800Rosenberg SM, McCue S, He J, Lafky JM, Carey LA, Galanis E, Leonard JP, Meyerhardt J, Ng K, Schwartz GK, Stock W, Paskett ED, Partridge AH, George SCancerAlliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer. 2024 03 01; 130(5):750-769.Cancer2023-11-02T00:00:002023Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.37993715Fan H, Xia S, Xiang J, Li Y, Ross MO, Lim SA, Yang F, Tu J, Xie L, Dougherty U, Zhang FQ, Zheng Z, Zhang R, Wu R, Dong L, Su R, Chen X, Althaus T, Riedell PA, Jonker PB, Muir A, Lesinski GB, Rafiq S, Dhodapkar MV, Stock W, Odenike O, Patel AA, Opferman J, Tsuji T, Matsuzaki J, Shah H, Faubert B, Elf SE, Layden B, Bissonnette BM, He YY, Kline J, Mao H, Odunsi K, Gao X, Chi H, He C, Chen JNatureTrans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043.Nature2023-11-22T00:00:002023Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.38039510Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin CBlood advancesSocioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.Blood Adv2024-01-09T00:00:002024Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.Authorship 16833825Authorship 16837033Authorship 1685332038017103Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, Blachly JS, Oakes CC, Buss J, Walker CJ, Orwick S, Jurinovic V, Rothenberg-Thurley M, Dufour A, Schneider S, Sauerland MC, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Subklewe M, Spiekermann K, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Uy GL, Stock W, Metzeler KH, Grimes HL, Byrd JC, Salomonis N, Herold T, Mims AS, Eisfeld AKLeukemiaSex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024 01; 38(1):45-57.Leukemia2023-11-28T00:00:002023Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).38073116Madero-Marroquin R, DuVall AS, Saygin C, Wang P, Gurbuxani S, Larson RA, Stock W, Patel AABritish journal of haematologyDurable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2023 Dec 10.Br J Haematol2023-12-10T00:00:002023Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.Authorship 1687037Authorship 16890923Authorship 1689351538106088Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, Murison A, Voisin V, Chan-Seng-Yue M, Cheng C, Qu C, Bailey C, Lear M, Witkowski MT, Zhou X, Peraza AZ, Gangwani K, Advani AS, Luger SM, Litzow MR, Rowe JM, Paietta EM, Stock W, Dick JE, Mullighan CGbioRxiv : the preprint server for biologySINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. bioRxiv. 2023 Dec 09.bioRxiv2023-12-09T00:00:002023SINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.38116118Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Monovich AC, Narina S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Pruett-Miller SM, Ryan RJH, Yang JJ, Evans WE, Savic DCell genomicsEpigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genom. 2023 Dec 13; 3(12):100442.Cell Genom2023-11-20T00:00:002023Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators.38150184Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock WBlood cancer discoveryAcute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27.Blood Cancer Discov2023-12-27T00:00:002023Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.Authorship 1691656Authorship 1692083538155245Parriott G, Hegermiller E, Morman RE, Frank C, Saygin C, Stock W, Bartom ET, Kee BLLeukemiaLoss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL. Leukemia. 2024 Mar; 38(3):491-501.Leukemia2023-12-28T00:00:002023Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.38215395Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JCBloodLong-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood. 2024 Jan 12.Blood2024-01-12T00:00:002024Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.Authorship 16950030Authorship 1695431238231126Roboz GJ, Sanz GF, Griffiths EA, Yee KWL, Kantarjian HM, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illes A, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell C, Hao Y, Keer HN, Azab M, Döhner HBlood advancesGuadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 Jan 17.Blood Adv2024-01-17T00:00:002024Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial.Authorship 1696171538252911Wolfson JA, Grimes AC, Nuno M, Kerber CL, Ramakrishnan S, Beauchemin M, Dickens D, Levine JM, Roth ME, Scialla M, Woods W, Vargas S, Boayue KB, Chang GJ, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, Liu JJ, Freyer DR, Sung L, Parsons SKJCO oncology practiceCharacteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL. JCO Oncol Pract. 2024 Jan 22; OP2300328.JCO Oncol Pract2024-01-22T00:00:002024Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL.https://voices.uchicago.edu/sayginlab/Saygin Lab38441062Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel AALeukemia & lymphomaTreatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Mar 05; 1-4.Leuk Lymphoma2024-03-05T00:00:002024Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.Authorship 17082811true1PROFESSORPROFESSORtrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorAuthorship 6539415Authorship 6696323Authorship 6717711Authorship 704447Authorship 7121115Authorship 724855Authorship 720045Authorship 740493Authorship 739339Authorship 7274956Authorship 7387711Authorship 769968Authorship 770155Authorship 7586419Authorship 770517Authorship 669793Authorship 73703525098428Raca G, Gurbuxani S, Zhang Z, Li Z, Sukhanova M, McNeer J, Stock WLeukemia & lymphomaRCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr; 56(4):1145-7.Leuk Lymphoma2014-08-26T00:00:002014RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia.25088808Mirza MK, Sukhanova M, Stölzel F, Onel K, Larson RA, Stock W, Ehninger G, Kuithan F, Zöphel K, Reddy P, Joseph L, Raca GLeukemia researchGenomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. Leuk Res. 2014 Sep; 38(9):1091-6.Leuk Res2014-05-21T00:00:002014Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays.23771005Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock WBone marrow transplantationA novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.Bone Marrow Transplant2013-06-17T00:00:002013A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.25403830Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi FBritish journal of haematologyREVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.Br J Haematol2014-11-17T00:00:002014REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.25207766Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CGThe New England journal of medicineTargetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11; 371(11):1005-15.N Engl J Med2014-09-11T00:00:002014Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.25468567Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJBloodA genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22; 125(4):680-6.Blood2014-12-02T00:00:002014A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.25365263Alachkar H, Mutonga MB, Metzeler KH, Fulton N, Malnassy G, Herold T, Spiekermann K, Bohlander SK, Hiddemann W, Matsuo Y, Stock W, Nakamura YOncotargetPreclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget. 2014 Dec 15; 5(23):12371-82.Oncotarget2014-12-15T00:00:002014Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.25483416Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock WInvestigational new drugsA phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.Invest New Drugs2014-12-09T00:00:002014A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.24077846Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RAHaematologicaAutologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014 Jan; 99(1):111-5.Haematologica2013-09-27T00:00:002013Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).10982293van Besien K, Bartholomew A, Stock W, Peace D, Devine S, Sher D, Sosman J, Chen YH, Koshy M, Hoffman RBone marrow transplantationFludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9.Bone Marrow Transplant2000-08-01T00:00:002000Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.24382782Kolitz JE, George SL, Benson DM, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA, Alliance for Clinical Trials in OncologyCancerRecombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 01; 120(7):1010-7.Cancer2013-12-31T00:00:002013Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.24383843Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJBritish journal of haematologyImatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.Br J Haematol2013-11-04T00:00:002013Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.11516091van Besien K, Keralavarma B, Devine S, Stock WLeukemiaAllogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia. 2001 Sep; 15(9):1317-25.Leukemia2001-09-01T00:00:002001Allogeneic and autologous transplantation for chronic lymphocytic leukemia.11157013Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman RJournal of clinical oncology : official journal of the American Society of Clinical OncologyPilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44.J Clin Oncol2001-02-01T00:00:002001Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.24816237Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz ASHaematologicaGeriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.Haematologica2014-05-09T00:00:002014Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.24160850Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock WLeukemia & lymphomaArsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32.Leuk Lymphoma2014-02-04T00:00:002014Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.24528179Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FRBritish journal of haematologyArsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503.Br J Haematol2014-02-14T00:00:002014Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.24564572Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien KLeukemia & lymphomaClofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73.Leuk Lymphoma2014-05-27T00:00:002014Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.24794707Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SWCancer cellMLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014 May 12; 25(5):652-65.Cancer Cell2014-05-01T00:00:002014MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.24300566Ramírez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJPharmacogenetics and genomicsA pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.Pharmacogenet Genomics2014-02-01T00:00:002014A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Authorship 79562325994952Kayser S, Walter RB, Stock W, Schlenk RFCurrent hematologic malignancy reportsMinimal residual disease in acute myeloid leukemia--current status and future perspectives. Curr Hematol Malig Rep. 2015 Jun; 10(2):132-44.Curr Hematol Malig Rep2015-06-01T00:00:002015Minimal residual disease in acute myeloid leukemia--current status and future perspectives.1010Authorship 80175225805810Curran E, Stock WBloodHow I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015 Jun 11; 125(24):3702-10.Blood2015-03-24T00:00:002015How I treat acute lymphoblastic leukemia in older adolescents and young adults.Authorship 80837426210198Weiss AR, Hayes-Lattin B, Kutny MA, Stock W, Stegenga K, Freyer DRSeminars in oncology nursingInclusion of Adolescents and Young Adults in Cancer Clinical Trials. Semin Oncol Nurs. 2015 Aug; 31(3):197-205.Semin Oncol Nurs2015-05-07T00:00:002015Inclusion of Adolescents and Young Adults in Cancer Clinical Trials.Chicago60637ILAuthorship 816421426052909Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura YBone marrow transplantationQuantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34.Bone Marrow Transplant2015-06-08T00:00:002015Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.Authorship 82600126351809Stock WClinical advances in hematology & oncology : H&ONovel drug targets in acute leukemia. Clin Adv Hematol Oncol. 2015 Aug; 13(8):493-5.Clin Adv Hematol Oncol2015-08-01T00:00:002015Novel drug targets in acute leukemia.Authorship 82714526296954Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian HThe Lancet. OncologySafety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110.Lancet Oncol2015-08-19T00:00:002015Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.Authorship 83365825787914Li Z, Stölzel F, Onel K, Sukhanova M, Mirza MK, Yap KL, Borinets O, Larson RA, Stock W, Sasaki MM, Joseph L, Raca GLeukemiaNext-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015 Oct; 29(10):2113-6.Leukemia2015-03-19T00:00:002015Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.Authorship 8399914Authorship 84002726500027Mutonga M, Tamura K, Malnassy G, Fulton N, de Albuquerque A, Hamamoto R, Stock W, Nakamura Y, Alachkar HTranslational oncologyTargeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Transl Oncol. 2015 Oct; 8(5):368-375.Transl Oncol2015-10-01T00:00:002015Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).26450903Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura YOncotargetT-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.Oncotarget2015-10-20T00:00:002015T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.Authorship 84316426385641Flowers CR, Brown JR, Rosenthal H, Stock W, Katzen HI, Cohen JB, Sinha R, Lakhanpal S, Leis JF, Waller EK, Jaye DLClinical lymphoma, myeloma & leukemiaA Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):694-8.Clin Lymphoma Myeloma Leuk2015-08-05T00:00:002015A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.Authorship 846222Authorship 84593425944470Liu H, Stock WLeukemia & lymphomaIs it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia? Leuk Lymphoma. 2015; 56(11):3005-7.Leuk Lymphoma2015-06-19T00:00:002015Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?26467815Uy GL, Hsu YM, Schmidt AP, Stock W, Fletcher TR, Trinkaus KM, Westervelt P, DiPersio JF, Link DCLeukemia researchTargeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res. 2015 Dec; 39(12):1437-42.Leuk Res2015-10-01T00:00:002015Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.Authorship 870138Authorship 87335226749023Muffly LS, Hlubocky FJ, Khan N, Wroblewski K, Breitenbach K, Gomez J, McNeer JL, Stock W, Daugherty CKCancerPsychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer. 2016 Mar 15; 122(6):954-61.Cancer2016-01-07T00:00:002016Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship.26812633Breitenbach K, Stock WJournal of adolescent and young adult oncologyIntergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. J Adolesc Young Adult Oncol. 2011 Jun; 1(2):107-8.J Adolesc Young Adult Oncol2011-10-04T00:00:002011Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.Authorship 89516526869630van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz AHaematologicaReduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.Haematologica2016-02-11T00:00:002016Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.Authorship 897821426912055Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz ASBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationFrequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.Biol Blood Marrow Transplant2016-02-19T00:00:002016Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.Authorship 90666227269126Pettit K, Stock W, Walter RBLeukemia & lymphomaIncorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leuk Lymphoma. 2016 07; 57(7):1527-33.Leuk Lymphoma2016-07-01T00:00:002016Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Authorship 922521026699199D'Angelo CR, Kocherginsky M, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz ASLeukemia & lymphomaIncidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13.Leuk Lymphoma2015-12-24T00:00:002015Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.Authorship 92437127462945Stock W, Larson RALeukemia & lymphomaNeurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. Leuk Lymphoma. 1991; 4(2):145-8.Leuk Lymphoma1991-01-01T00:00:001991Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report.Authorship 927121226892479DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock WLeukemia & lymphomaClinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.Leuk Lymphoma2016-02-18T00:00:002016Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.27063598Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HPLeukemiaComprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 08; 30(8):1672-81.Leukemia2016-04-11T00:00:002016Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.Authorship 93339627292104Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani ASThe New England journal of medicineInotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.N Engl J Med2016-06-12T00:00:002016Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.Authorship 6045914Authorship 6124043Authorship 614542Authorship 600381Authorship 605754Authorship 60640811280803Hu YJ, Korotkov KV, Mehta R, Hatfield DL, Rotimi CN, Luke A, Prewitt TE, Cooper RS, Stock W, Vokes EE, Dolan ME, Gladyshev VN, Diamond AMCancer researchDistribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res. 2001 Mar 01; 61(5):2307-10.Cancer Res2001-03-01T00:00:002001Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene.23169518O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian HJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20; 31(6):676-83.J Clin Oncol2012-11-19T00:00:002012High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.23334668Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CGNature geneticsThe genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013 Mar; 45(3):242-52.Nat Genet2013-01-20T00:00:002013The genomic landscape of hypodiploid acute lymphoblastic leukemia.22744771Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RACancerDose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.Cancer2012-06-28T00:00:002012Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.23088744Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien KLeukemia & lymphomaImmune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9.Leuk Lymphoma2013-03-01T00:00:002013Immune reconstitution after combined haploidentical and umbilical cord blood transplant.23142329Van Besien K, Liu H, Jain N, Stock W, Artz ABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationUmbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013 May; 19(5):682-91.Biol Blood Marrow Transplant2012-11-08T00:00:002012Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.23385613Liu H, Stock W, Bishop MRCurrent opinion in hematologyExpanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. Curr Opin Hematol. 2013 Mar; 20(2):115-22.Curr Opin Hematol2013-03-01T00:00:002013Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies.Authorship 960616027713533Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA, Malnassy G, Ma T, Garg M, Ding LW, Sun QY, Chien W, Ikezoe T, Lill M, Biondi A, Larson RA, Powell BL, Lübbert M, Chng WJ, Tien HF, Heuser M, Ganser A, Koren-Michowitz M, Kornblau SM, Kantarjian HM, Nowak D, Hofmann WK, Yang H, Stock W, Ghavamzadeh A, Alimoghaddam K, Haferlach T, Ogawa S, Shih LY, Mathews V, Koeffler HPLeukemiaComprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016 12; 30(12):2430.Leukemia2016-10-07T00:00:002016Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.27624549Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wang ES, Hoke E, Mrózek K, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA, Alliance for Clinical Trials in OncologyLeukemiaMaintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39.Leukemia2016-09-13T00:00:002016Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).27776115Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrózek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG, St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome ProjectNature geneticsDeregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016 12; 48(12):1481-1489.Nat Genet2016-10-24T00:00:002016Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.Authorship 9667747Authorship 966621Authorship 96897527618250Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM, Larson RA, Evans WEClinical pharmacology and therapeuticsAn Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther. 2017 03; 101(3):391-395.Clin Pharmacol Ther2016-11-16T00:00:002016An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.27824051Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CGNature communicationsGenomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun. 2016 11 08; 7:13331.Nat Commun2016-11-08T00:00:002016Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.27855558Yap KL, Furtado LV, Kiyotani K, Curran E, Stock W, McNeer JL, Kadri S, Segal JP, Nakamura Y, Le Beau MM, Gurbuxani S, Raca GLeukemia & lymphomaDiagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958.Leuk Lymphoma2016-11-17T00:00:002016Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).DanielArberDaniel Arber0.000000000000000.000000000000003406Arber, DanielProfessorAuthorship 975563027870571Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CGJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol. 2017 Feb; 35(4):394-401.J Clin Oncol2016-11-21T00:00:002016High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.Authorship 9789333Authorship 98237527019981Alachkar H, Fulton N, Sanford B, Malnassy G, Mutonga M, Larson RA, Bloomfield CD, Marcucci G, Nakamura Y, Stock WThe pharmacogenomics journalExpression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 06; 17(3):274-279.Pharmacogenomics J2016-03-29T00:00:002016Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.27959731Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJThe New England journal of medicineTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036.N Engl J Med2016-11-24T00:00:002016TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.27622953Muffly L, Lichtensztajn D, Shiraz P, Abrahão R, McNeer J, Stock W, Keegan T, Gomez SLCancerAdoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer. 2017 Jan 01; 123(1):122-130.Cancer2016-09-13T00:00:002016Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.Authorship 990781227626698Sharma S, Galanina N, Guo A, Lee J, Kadri S, Van Slambrouck C, Long B, Wang W, Ming M, Furtado LV, Segal JP, Stock W, Venkataraman G, Tang WJ, Lu P, Wang YLOncotargetIdentification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.Oncotarget2016-10-18T00:00:002016Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.